Tenon(R) Medical Reports Fourth Quarter and Full Year 2025 Financial Results ~ Fourth Quarter 2025 Revenue of $1.5 Million, a 92% Increase Compared to Prior Year ~~ Record Full Year 2025 Revenue of $3.9 Million, a 20% Increase compared to Prior Year, Driven by Strong Second Half Momentum ~~ Record Full Year 2025 Gross Profit of $2.4 Million, a 38% Increase Compared to Prior

#TNON Tenon(R) Medical Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/TNON/tenon-r-medica...

#TNON Tenon(R) Medical Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/TNON/tenon-r-medica...

#TNON Tenon Medical(R) Announces Pricing of At-The-Market PIPE Financing

www.stocktitan.net/news/TNON/tenon-medical-...

Tenon(R) Medical Announces Second Peer-Reviewed Catamaran Mainsail(TM) Study Publication, Underscores Robust and Sustainable Clinical Outcomes Out to 12 Months Tenon Medical (NASDAQ:TNON) announced compelling 12-month results from its MAINSAIL™ study evaluating the Catamaran® SI Joint Fusion System. The study showed significant clinical improvements, with pain scores (VAS) decreasing from 78.8mm to 23.0mm and disability scores (ODI) improving from 51.6% to 20.8%. 83% of patients demonstrated unequivocal fusion evidence at 12 months.The study, involving 24 patients across six U.S. clinical sites, reported no serious adverse events and high patient satisfaction, with 83.3% reporting satisfaction at 12 months. The surgical efficiency was notable, with 45.7% of procedures completed in under 45 minutes. These results exceed average improvements reported in previous literature for SI joint fusion procedures.

#TNON Tenon(R) Medical Announces Second Peer-Reviewed Catamaran Mainsail(TM) Study Publication, Underscores Robust and Sustainable Clinical Outcomes Out to 12 Months

www.stocktitan.net/news/TNON/tenon-r-medica...

Smaller Profile SI Joint Fusion Device: Tenon Medical Launches Catamaran SE After 1,000+ Successful Implants Tenon Medical introduces smaller Catamaran SE implant for SI joint fusion, expanding surgical options. System features dedicated instruments, manual drilling option, and builds on 1,000+ device track record.

#TNON Tenon(R) Medical Announces the Full Market Launch of the Catamaran(R) SE SI Joint Fusion System

www.stocktitan.net/news/TNON/tenon-r-medica...

Tenon Medical Narrows Losses to $2.8M as Strategic Acquisition Sets Stage for Growth Tenon Medical reduces Q2 losses by 26% while integrating SiVantage portfolio. FDA clearance expands Catamaran device market reach. $7.8M cash position fuels growth. See details.

#TNON Tenon Medical Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/TNON/tenon-medical-...

Tenon Medical, SIJ Treatment Pioneer, Sets Q2 2025 Earnings Call with Analyst Q&A Session Medical device innovator Tenon reveals Q2 2025 results August 13. Join the earnings call with analyst Q&A to explore SIJ treatment advances. Get insights.

#TNON Tenon Medical, Inc. Announces Timing of Second Quarter 2025 Financial Results

www.stocktitan.net/news/TNON/tenon-medical-...

BREAKING NEWS: ( NASDAQ: #TNON ) Tenon Medical Acquires SiVantage Assets to Expand Sacro-Pelvic Fusion Capabilities

Breaking News: ( NASDAQ: #TNON ) Tenon Medical(R) Expands Sacro-Pelvic Fusion Portfolio with Strategic Asset Acquisition

NASDAQ: #TNON
#TenonMedical strengthens its spine surgery solutions with the acquisition of SiVantage assets, expanding its sacro-pelvic fusion portfolio to enhance patient outcomes.
prismmarketview.com/tenon-medica...

Tenon Medical Expands Sacroiliac Joint Treatment with Game-Changing SiVantage Acquisition Tenon Medical strengthens sacroiliac joint fusion capabilities with SiVantage's SImmetry technology portfolio. Key executives join to accelerate growth. See expansion details.

#TNON Tenon Medical(R) Expands Sacro-Pelvic Fusion Portfolio with Strategic Asset Acquisition

www.stocktitan.net/news/TNON/tenon-medical-...

Breakthrough: Tenon Medical's SI Joint System Gets FDA Green Light for Complex Spine Surgery Applications New FDA indication enables Catamaran system use in spinal fusion procedures. Clinical data shows enhanced stabilization without added complications. See surgical outcomes.

#TNON Tenon Medical Announces Initial Case Series Utilizing Catamaran(R) SI Joint Fusion System to Enhance Stabilization of the SI Joint for Patients Undergoing Lumbar Fusion

www.stocktitan.net/news/TNON/tenon-medical-...

Tenon Medical, Inc. Announces Timing of First Quarter 2025 Financial Results Tenon Medical (NASDAQ: TNON), a healthcare company focused on Sacroiliac Joint (SIJ) disorders, has scheduled its Q1 2025 financial results announcement for May 13, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern Time, featuring a Q&A session with covering analysts. Investors can access the call through: US Dial-in: 1-877-407-0792 International Dial-in: 1-201-689-8263 Participants are advised to dial in 10 minutes before the call starts. A replay will be available through May 28, 2025, via the company's IR website or by phone (US: 1-844-512-2921, International: 1-412-317-6671) using access code 13752970.

#TNON Tenon Medical, Inc. Announces Timing of First Quarter 2025 Financial Results

www.stocktitan.net/news/TNON/tenon-medical-...

🚀 Exciting times for #TNON! Trading at $2.38 with bullish momentum, an 8-day EMA of $2.15, and a positive MACD. RSI at 59 suggests room to grow. FDA clearance adds optimism, but watch for volatility. Consider entry at $2.35, targeting $2.60 & $2.80. 📈 #FeetrAI

🚀 Exciting times for #TNON! With FDA clearance boosting its Caramaran SI Joint Fusion System, Tenon Medical is on the rise. Trading at $2.38, bullish indicators suggest more gains ahead. Consider a LONG position targeting $2.60 & $2.80. 📈 #FeetrAI #StockAlert

🚀 Exciting times for #TNON! Trading at $2.38 with bullish momentum and a strong MACD, Tenon Medical's recent FDA clearance is a game-changer. Despite a $1.5M offering, technicals suggest room to grow. Enter at $2.35, target $2.60 & $2.80. Stay sharp, volatility ahead! 📈 #Stocks #FeetrAI

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Thu Mar 27th - #IBRX #WULF #WOOF #CORZ #BTE #TNON #QBTS #IQ #VLRS #BKD #CLSK #TDOC #SPCE #SMR #SLNO #RAMP #MLGO #RAMP #LGMK #DMN #APLD - More: crystalequityresearch.com/SmCpStr/ - #smallcap

🚀 Exciting times for #TNON! With FDA clearance and a $1.5M offering, Tenon Medical is on the move. Bullish momentum spotted with MACD & RSI > 60. Consider a cautious long at $2.55, targeting $2.85 & $3.00. Stop loss at $2.40. Stay alert for market shifts! 📈 #FeetrAI

🚀 Exciting times for #TNON! With FDA clearance and a $1.5M offering, the stock is on a bullish run. MACD is positive, RSI at 60, signaling potential gains. Consider a LONG position at $2.40, targeting $3.00 & $3.50. Stay sharp—volatility is high! 📈 #FeetrAI

Healthcare Fund Backs Tenon Medical with $2.5M Investment: What This Means for SI Joint Treatment Healthcare-focused institutional investor commits $2.5M to SI joint treatment innovator Tenon Medical. Includes strategic warrant coverage. See investment implications.

#TNON Tenon Medical, Inc. Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/TNON/tenon-medical-...

🚀 Exciting times for #TNON! With high trading volume and bullish momentum, Tenon Medical is on the move. But watch out—RSI suggests it's overbought. 📈 Consider a short position with targets at $3.20 & $2.80. Stop loss at $4.60. Stay sharp, traders! #FeetrAI #StockWatch

Just In: ( NASDAQ: #TNON ) Top Stocks with News: SYTA, TNON, POAI, ALMS, DATS, and MLGO

Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Tenon Medical (NASDAQ:TNON), a company focused on sacroiliac joint disorders treatment, has announced a registered direct offering and concurrent private placement priced at-the-market under Nasdaq rules. The company will issue 733,500 shares of common stock at $2.00 per share to a single healthcare focused institutional investor.In the concurrent private placement, Tenon will issue warrants to purchase up to 733,500 additional shares at an exercise price of $2.00 per share, exercisable immediately with a five-year expiration. The offering, expected to close around March 26, 2025, aims to raise approximately $1.5 million in gross proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent.

#TNON Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/TNON/tenon-medical-...

Just In: ( NASDAQ: #TNON ) Tenon Medical Secures FDA Nod for Catamaran SI Joint Fusion System's New Role in Spinal Fusion

Major FDA Win: Tenon's SI Joint System Gets Green Light for Complex Spine Surgery New FDA clearance enables Catamaran system's use in thoracolumbar fusion, expanding treatment options for complex spine surgery. Full market impact analysis inside.

#TNON Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion

www.stocktitan.net/news/TNON/tenon-medical-...

Tenon Medical Reports Fourth Quarter and Full Year 2024 Financial Results Tenon Medical (NASDAQ:TNON) reported its Q4 and full-year 2024 financial results, showing mixed performance. Full-year revenue reached $3.3 million, marking a 12% increase from 2023, with improved gross profit of $1.7 million and gross margin of 52%.Q4 2024 revenue remained flat at $0.8 million compared to Q4 2023, while gross profit decreased to $353,000 from $559,000, with margins declining to 46% from 69%. The company's Catamaran SI Joint Fusion System achieved significant milestones, including positive interim results from the MAINSAIL Study and completion of over 1,000 surgical procedures.Notable developments include the expansion of their patent portfolio to twelve U.S. and international patents, successful initial clinical procedures with the new Catamaran SE platform, and securing an additional $3M in capital in March 2025. The company plans a national commercial launch of Catamaran SE in mid-2025.

#TNON Tenon Medical Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/TNON/tenon-medical-...

🚀 Exciting times for #TNON! Trading at $1.22, it's showing short-term bullish momentum with a positive MACD and recent volume uptick. Consider a cautious long position with targets at $1.25 & $1.30. Stay sharp, as market headwinds could impact moves. #FeetrAI #Stocks 📈

🚨 Bearish vibes for #TNON! Trading at $1.14, it's below key moving averages with RSI & MACD signaling more selling pressure. 📉 Consider a short position with targets at $1.10 & $1.05, stop loss at $1.18. Stay cautious in this volatile market! #FeetrAI #StockAnalysis